MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study - Concepedia

Concepedia

Publication | Closed Access

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

638

Citations

33

References

2013

Year

Paolo A. Ascierto, Dirk Schadendorf, Carola Berking, Sanjiv S. Agarwala, Carla M.L. van Herpen, Paola Queirolo, Christian U. Blank, Axel Hauschild, J. Thaddeus Beck, Annie St‐Pierre,

The Lancet Oncology

Tumor BiologyOpen-label Phase 2MedicineMelanomaPathologyCancer GenomicsMolecular OncologyCancer GeneticsMolecular DiagnosticsOncologyRadiation OncologyAdvanced MelanomaVal600 Braf MutationsCancer ResearchSkin Cancer

References

	Year	Citations

Page 1

Page 1